Nubeqa

Chemical Namedarolutamide
Dosage FormTablet (oral; 300 mg)
Drug ClassReceptor antagonists
SystemMale reproductive
CompanyBayer HealthCare Pharmaceuticals Inc.
Approval Year2019

Indication

  • Nubeqa is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Last updated on 2/1/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nubeqa (darolutamide) Prescribing Information 2019Bayer Healthcare
Document TitleYearSource
Advanced prostate cancer: AUA/ASTRO/SUO guideline. 2020American Urological Association Education and Research